Gland Pharma

Stocks to Watch, Dec 12: Jubilant FoodWorks, SBI, Vedanta, Swiggy, Emami

Stocks to Watch, Dec 12: From Swiggy to Jubilant Foodworks, here are some stocks that will be on investors radar today

Here's why Gland Pharma share was up 3% on December 3; details here

The uptick in Gland Pharma share came after the company said that it has received approval from the United States Food and Drug Administration (US FDA) for Latanoprost Ophthalmic Solution

Nifty Pharma jumps over 2%: Analysts decode the drivers behind the rally

Individually, Cipla soared up to 3.68 per cent to hit an intraday high of Rs 1,547.70 per share, while Sun Pharma soared up to 3.30 per cent to hit an intraday high of Rs 1,791.60 per share

Upper-teens EPS growth likely for Gland Pharma in next two financial years

Analysts are downgrading optimistic EPS estimates for FY25 and FY26, due to continuing slowdown in US sales and a temporary issue at Cenexi's site in Belgium

Gland Pharma soars 13% on better than expected Q2 performance

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Gland Pharma Q2FY25 results: Net profit falls 15.7% to Rs 164 crore

The company reported consolidated net profit of Rs 164 crore ($19.5 million) for the quarter ended Sept. 30, a 15.7 per cent decrease from the year-ago period

ACC, 2 pvt banks among 8 midcap stocks turn favourable on tech charts

The Nifty MidCap index has gained 3% from its recent low in the last three days. Amid this these 8 stocks have seen key momentum oscillators turn favourable on the daily chart.

Gland Pharma tanks 9% on weak June quarter show; Q1 profit drops 26%

The share price fell after the company reported a weak set of June quarter (Q1FY25) results.

Gland Pharma Q1 FY25 results: Net profit falls 26%, revenue rises 16%

The decrease in the group's consolidated Ebitda margin is being attributed to the negative Ebitda reported by Cenexi, its recent acquisition

Gland Pharma promoter Fosun divests 6% stake for Rs 1,754 cr via bulk deal

Fosun Pharma, one of the promoters of Gland Pharma, on Wednesday divested a 6 per cent stake for Rs 1,754 crore through an open market transaction. Chinese drug firm Fosun Pharma, through its arm Fosun Pharma Industrial Pte, offloaded the shares of Hyderabad-based Gland Pharma through a bulk deal on the BSE. According to the bulk deal data available on the BSE, Fosun Pharma Industrial Pte disposed of 99 lakh shares or a 6 per cent stake in Gland Pharma. The shares were sold at an average price of Rs 1,771.81 apiece, taking the deal size to Rs 1,754.09 crore. After the stake sale, Fosun Pharma's shareholding in Gland Pharma has declined to 51.86 per cent from 57.86 per cent. Meanwhile, UBS Principal Capital Asia picked up 8.25 lakh shares, amounting to a 0.5 per cent stake in Gland Pharma. The shares were purchased at an average price of Rs 1,771.05 per piece, taking the transaction value to Rs 146.11 crore. Details of the other buyers of Gland Pharma's shares could not be ...

Indus Towers, Tata Technologies among seven stocks to track on June 19

At 6:37 AM, GIFT Nifty futures indicated a robust start, trading up 85 points at 23,653 compared to Nifty futures' previous close

Gland Pharma surges 11% amidst stellar Q4 results; profits grow two fold

On Wednesday, Gland Pharma reported a two fold jump or 145 per cent increase in consolidated net profit, reaching Rs 192.4 crore for the January-March period of FY24

Gland Pharma Q4 results: Net profit jumps over two-fold to Rs 192 crore

Gland Pharma on Wednesday said its consolidated profit after tax (PAT) surged over two-fold to Rs 192 crore for the March quarter. The company has reported a PAT of Rs 79 crore in the year-ago period, the Hyderabad-based drug firm said in a statement. Revenue from operations rose to Rs 1,537 crore in the fourth quarter of FY24 as against Rs 785 crore in the year-ago period, it said. For the year ended March 31, 2024, the company reported a PAT of Rs 772 crore as against Rs 781 crore in 2022-23 fiscal. Revenue from operations rose to Rs 5,665 crore last fiscal as against Rs 3,625 crore in FY23. "This year marked a significant rebound for our base business, and we began an exciting new chapter as we completed our first international acquisition, Cenexi, in Europe," Gland Pharma MD and CEO Srinivas Sadu said. Despite the dynamic business landscape, the drugmaker has shown resilience and delivered a performance that positions it well for continued growth and success, he added. "We s

Private equity company Bain Capital sells residual stake in Axis Bank

Among the buyers were a clutch of domestic as well as foreign funds

Two entities sell 4.9% stake in Gland Pharma for Rs 1,411 cr via open mkt

Two entities -- Lakumi Trust and Nicomac Machinery -- on Tuesday divested a 4.9 per cent stake in Gland Pharma for Rs 1,411 crore through open market transactions. Lakumi Trust and Nicomac Machinery Pvt Ltd disposed of 81.20 lakh shares of Gland Pharma in separate bulk deals on the National Stock Exchange (NSE). As per the data on the NSE, Lakumi Trust offloaded 61.65 lakh shares of Gland Pharma and Nicomac Machinery sold more than 19.55 lakh shares, amounting to a 3.74 per cent stake and an 1.18 per cent stake in the company. The shares were sold within the price range of Rs 1,735.31-1,739.10 apiece, taking the transaction value to Rs 1,411.57 crore. After the latest transaction, Nicomac Machinery sold its entire 1.18 per cent stake and exited the firm. Details of the buyers of Gland Pharma's shares could not be ascertained. Shares of Gland Pharma fell 2.83 per cent to close at Rs 1,807 apiece on the NSE. China's Fosun Pharma is the promoter of Gland Pharma and holds a 57.86 pe

Gland Pharma slips 7% after over 5% equity changes hands via block deal

According to media reports, two entities - Nicomac Machinery and RP Advisory Services - were looking to sell up to 4.4 per cent stake in Gland Pharma through block deals on Tuesday

Gland Pharma soars 7% on USFDA approval for breast cancer drug

The Eribulin Mesylate injection is indicated for treating patients diagnosed with metastatic breast cancer (mBC) who have undergone at least two rounds of chemotherapy for managing metastatic disease

Gland Pharma Q3 results: Net porfit at Rs 192 cr, revenue at Rs 1,545 cr

Gland Pharma on Wednesday said its consolidated Profit After Tax (PAT) stood at Rs 192 crore for the December quarter. The drug firm had reported a PAT of Rs 232 crore in the year-ago period. The company's revenue from operations stood at Rs 1,545 crore for the October-December period, up from Rs 938 a year ago. The results for the quarter under review and the nine months of the current fiscal are not comparable to the earlier periods of the previous year due to the inclusion of Cenexi results, the Hyderabad-based company said. On November 29, 2022, the Hyderabad-based drug Contract Development and Manufacturing Company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to 120 million euros, marking its foray into the international markets. "In the ex-Cenexi base business, we are happy to keep up with the growth aspirations, and the performance has been encouraging with the introduction of new products and improved volumes of the current basket," Gland .

Gland Pharma Q2 result: Net profit fell 20% to Rs 194 cr on higher expenses

Gland Pharma reported a nearly 32% jump in revenue from operations to Rs 1,373 crore, driven by higher sales from the acquisition of the French pharmaceutical group Cenexi in January

Stocks to Watch today, Aug 28: RIL, Jio Fin, BEL, Adani group, Gland Pharma

Stocks to Watch on Monday, August 28, 2023: The 46th Annual General Meeting (AGM) of Reliance Industries will take place at 2 PM today where Chairman Mukesh Ambani will address the shareholders